Loading cancer entity…
Loading cancer entity…
Clinical trials
8,122 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,291)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02467010 | Relapse Myeloma; Cyclofosfamide; Bortezomib; Maintenance(REMM) | completed | Phase 2 | 73 | University Medical Center GroningenOTHER | 1 | Jun 9, 2015 | clinicaltrials |
| NCT01843998 | Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL) | withdrawn | Phase 2 | 0 | Stefan Schieke MDOTHER | 1 | Jun 4, 2015 | clinicaltrials |
| NCT00453427 | Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas(ACCAPELA) | completed | Phase 1 / Phase 2 | 20 | Ontario Clinical Oncology Group (OCOG)OTHER | 1 | Jun 3, 2015 | clinicaltrials |
| NCT02456207 | A Pharmacokinetic Study Comparing SCT400 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma | unknown | Phase 2 | 80 | Sinocelltech Ltd.INDUSTRY | 1 | May 28, 2015 | clinicaltrials |
| NCT00129415 | Ultraviolet (UVA and UVB) Light Therapy in the Treatment of Inflammatory Skin Conditions | terminated | Phase 1 / Phase 2 | 28 | University of MichiganOTHER | 1 | May 22, 2015 | clinicaltrials |
| NCT00998049 | Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant | completed | Phase 2 | 40 | Mayo ClinicOTHER | 1 | May 14, 2015 | clinicaltrials |
| NCT00778752 | Dose-finding of Lenalidomide as Maintenance in Multiple Myeloma | completed | Phase 1 / Phase 2 | 24 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | May 13, 2015 | clinicaltrials |
| NCT02150928 | An Open-Label, Single-Arm, Multicenter Pharmacokinetic Study of Intramuscular Erwinaze® (Asparaginase Erwinia Chrysanthemi)/Erwinase® (Crisantaspase) | withdrawn | Phase 2 | 0 | Jazz PharmaceuticalsINDUSTRY | 1 | May 13, 2015 | clinicaltrials |
| NCT02431403 | ESHAP-Imatinib for Refractory/Relapsed Non-Hodgkin's Lymphoma | unknown | Phase 1 / Phase 2 | 94 | Pusan National University HospitalOTHER | 1 | May 5, 2015 | clinicaltrials |
| NCT01160484 | Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma | completed | Phase 2 | 40 | OncotherapeuticsINDUSTRY | 1 | May 4, 2015 | clinicaltrials |
| NCT00395967 | AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF Alone | terminated | Phase 2 | 5 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | May 1, 2015 | clinicaltrials |
| NCT02082405 | Bortezomib, Dexamethasone, and Cyclophosphamide in Treating Older Patients With Multiple Myeloma | withdrawn | Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 0 | Apr 24, 2015 | clinicaltrials |
| NCT00092274 | Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | GlaxoSmithKlineINDUSTRY | 1 | Apr 21, 2015 | clinicaltrials |
| NCT00503763 | Efficacy and Safety of Statin on the Course of Progressive Smoldering Multiple Myeloma(PSMMSS) | withdrawn | Phase 2 | 0 | Meir Medical CenterOTHER | 0 | Apr 16, 2015 | clinicaltrials |
| NCT00003210 | Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin's Lymphoma or Hodgkin's Disease | completed | Phase 2 | 105 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2015 | clinicaltrials |
| NCT00958256 | Study of Bortezomib in Combination With Cyclophosphamide and Rituximab | completed | Phase 2 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 13, 2015 | clinicaltrials |
| NCT02399189 | MT-R Followed by Autologous Stem Cells Transplantation in Newly-diagnosed Primary Central Nervous System Lymphoma | unknown | Phase 2 | 39 | Jun ZhuOTHER | 1 | Apr 13, 2015 | clinicaltrials |
| NCT00706953 | A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed Multiple Myeloma Previously Treated With Bortezomib | withdrawn | Phase 2 | 0 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 0 | Apr 6, 2015 | clinicaltrials |
| NCT01062230 | Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma | terminated | Phase 2 | 6 | University of ArkansasOTHER | 1 | Apr 6, 2015 | clinicaltrials |
| NCT00426855 | Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL) | completed | Phase 1 / Phase 2 | 12 | Peter MoosmannOTHER | 0 | Apr 3, 2015 | clinicaltrials |
| NCT00210392 | VELCADE in MALT Lymphoma Pretreated With More Than One Prior Systemic Therapy | terminated | Phase 2 | 12 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 1 | Mar 30, 2015 | clinicaltrials |
| NCT00077961 | Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHL | terminated | Phase 1 / Phase 2 | 49 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 26, 2015 | clinicaltrials |
| NCT00099593 | Immunization Against Tumor Cells in Sezary Syndrome | completed | Phase 2 | 17 | University of PittsburghOTHER | 1 | Mar 25, 2015 | clinicaltrials |
| NCT00066638 | FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Mar 17, 2015 | clinicaltrials |
| NCT00185679 | Haploid Allogeneic Transplant Using the CliniMACS System | terminated | Phase 2 | 13 | Ginna LaportOTHER | 1 | Mar 9, 2015 | clinicaltrials |
| NCT02353468 | Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant | terminated | Phase 2 | 3 | University of Colorado, DenverOTHER | 1 | Mar 9, 2015 | clinicaltrials |
| NCT02353572 | Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma | terminated | Phase 1 / Phase 2 | 3 | University of Colorado, DenverOTHER | 1 | Mar 9, 2015 | clinicaltrials |
| NCT00002849 | S9628 Dexamethasone Plus Interferon Alfa in Treating Patients With Primary Systemic Amyloidosis | completed | Phase 2 | 93 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 6, 2015 | clinicaltrials |
| NCT01055301 | S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma | withdrawn | Phase 2 | 0 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 6, 2015 | clinicaltrials |
| NCT00051701 | Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's Lymphoma | terminated | Phase 1 / Phase 2 | 61 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 5, 2015 | clinicaltrials |
| NCT00516191 | A Phase I/II Study of Liposomal Doxorubicin (Doxil)/Melphalan/Bortezomib (Velcade) in Relapsed/Refractory Multiple Myeloma(DMV) | withdrawn | Phase 1 / Phase 2 | 0 | University of California, San FranciscoOTHER | 1 | Mar 4, 2015 | clinicaltrials |
| NCT01198665 | RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas(RADCHOP) | completed | Phase 1 / Phase 2 | 46 | Samsung Medical CenterOTHER | 1 | Mar 3, 2015 | clinicaltrials |
| NCT01238159 | Concomitant Chemo-radiotherapy Followed by MIDLE Chemotherapy in Stage I/II Extranodal NK/T-cell Lymphoma | completed | Phase 2 | 30 | Samsung Medical CenterOTHER | 1 | Mar 3, 2015 | clinicaltrials |
| NCT00337987 | A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma | completed | Phase 2 | 49 | Yale UniversityOTHER | 1 | Feb 27, 2015 | clinicaltrials |
| NCT00529503 | A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL | terminated | Phase 2 | 151 | Seagen Inc.INDUSTRY | 10 | Feb 25, 2015 | clinicaltrials |
| NCT00832234 | Bortezomib, Dexamethasone, and Rituximab in Untreated Waldenstroms Macroglobulinemia(BDR-WM) | completed | Phase 2 | 59 | European Myeloma Network B.V.NETWORK | 1 | Feb 18, 2015 | clinicaltrials |
| NCT00809276 | Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY | completed | Phase 1 / Phase 2 | 92 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 16, 2015 | clinicaltrials |
| NCT01302366 | A Trial of TBL12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma | terminated | Phase 2 | 20 | NYU Langone HealthOTHER | 1 | Feb 12, 2015 | clinicaltrials |
| NCT00916045 | Pilot Study of Unrelated Cord Blood Transplantation | terminated | Phase 2 | 40 | King's College Hospital NHS TrustOTHER | 1 | Feb 11, 2015 | clinicaltrials |
| NCT01849848 | Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma | completed | Phase 2 | 17 | SymBio PharmaceuticalsINDUSTRY | 1 | Feb 6, 2015 | clinicaltrials |
| NCT00440583 | The Response Study of Yt90-Zevalin in Patients With Diffuse Large B-cell Lymphoma After 6 Cycles of CHOP | completed | Phase 2 | 15 | Mahidol UniversityOTHER | 1 | Jan 30, 2015 | clinicaltrials |
| NCT00908232 | Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VD(SEQUENTIAL) | completed | Phase 2 | 163 | Janssen-Cilag International NVINDUSTRY | 10 | Jan 15, 2015 | clinicaltrials |
| NCT00719901 | Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Jan 12, 2015 | clinicaltrials |
| NCT01078441 | Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant | terminated | Phase 2 | 2 | National Cancer Institute (NCI)NIH | 1 | Jan 12, 2015 | clinicaltrials |
| NCT00435916 | Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell Lymphoma | completed | Phase 2 | 46 | Seagen Inc.INDUSTRY | 1 | Jan 7, 2015 | clinicaltrials |
| NCT00193492 | A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma | completed | Phase 2 | 60 | SCRI Development Innovations, LLCOTHER | 1 | Jan 5, 2015 | clinicaltrials |
| NCT00220285 | Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's Lymphoma | completed | Phase 2 | 45 | BayerINDUSTRY | 1 | Dec 30, 2014 | clinicaltrials |
| NCT00079755 | Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphoma | completed | Phase 2 | 80 | Seagen Inc.INDUSTRY | 1 | Dec 18, 2014 | clinicaltrials |
| NCT01998893 | A Study of MabThera/Rituxan (Rituximab) in Patients With Relapsed Centroblastic Centrocytic Non-Hodgkin's Lymphoma | completed | Phase 2 | 38 | Hoffmann-La RocheINDUSTRY | 1 | Dec 3, 2014 | clinicaltrials |
Data updated 24 days agoSource updated Jun 9, 2015source: clinicaltrials